Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

By Gauthier Serge  

Current Medical Research and Opinion, Vol. 29, Iss. 8, 2013-08 ,pp. : 989-1000

Informa Healthcare

Access to resources Recommend Favorite

Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study

By Mets Tony   Vandewoude Maurits   Jacquy Jean   Deblander Anne   MacDonald Karen   Sloesen Anne   Abraham Ivo    

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2485-2501

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 7, 2015-06 ,pp. : 912-918

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessing the psychosocial consequences of epilepsy: a community-based study

By O'Donoghue M. F.   Goodridge D. M. G.   Redhead K.   Sander J. W. A. S.   Duncan J. S.  

British Journal of General Practice, Vol. 49, Iss. 440, 1999-03 ,pp. : 211-214

Royal College of General Practitioners

Access to resources Recommend Favorite